Bilikere Srinivasa Rao Dwarakanath | |
Birth Date: | 4 August 1955 |
Birth Place: | Bangalore, India |
Citizenship: | India |
Nationality: | Indian |
Fields: | Biochemist and Radiation Biologist |
Workplaces: | Institute of Nuclear Medicine and Allied Sciences |
Alma Mater: | Central College, Bangalore |
Doctoral Advisor: | Viney K Jain |
Known For: | Cancer Therapy and Radioprotection |
Awards: | Indira Vasudevan Award, Annual Award of SCRAC |
Bilikere Srinivasa Rao Dwarakanath (born 4 August 1955) is a molecular biologist and a radiation biologist, working on 2-Deoxy-D-glucose therapy in cancer research. His current research interests are experimental oncology, radiobiology, biological radioprotection and cell signaling in cancer therapy.[1] He is currently the Joint Director of the Institute of Nuclear Medicine and Allied Sciences (INMAS), DRDO, Head, Division of Radiation Biosciences, INMAS, and Adjunct Faculty at the Dr. B. R. Ambedkar Center for Biomedical Research (ACBR), University of Delhi.[2]
He is one of the members of the three-member committee (along with Prof. S.C. Pancholi of the Nuclear Science Centre and Prof. N.C. Goomer of Board of Radiation and Isotope Technology) that was constituted by the Delhi University to probe the incident of radioactivity leakage in a Delhi scrap market, the source of the radioactive material was traced to the chemistry department of the university.[3]
Dwarakanath was born in Bangalore, Karnataka, India, to B. N. Srinivasa Rao and B. S. Padmavathi as the third among 5 siblings. He obtained his B.Sc. degree in Physics, Chemistry and Mathematics from National College and his M.Sc. degree in Physics from Central College, Bangalore. He obtained his Ph.D. degree from Bangalore University, working at the National Institute of Mental Health and Neurosciences under the radiation biologist Viney K. Jain.
Dwarakanath joined INMAS, Delhi in April 1994 as "Scientist D".[4] He is currently the Joint Director and HOD, Division of Radiation Biosciences, at INMAS.[5] He has been advocating the use of 2-deoyx-D-glucose as an adjuvant to radiotherapy for the treatment of cancer.[6]